Journal

How Dose Escalation Changes Tirzepatide Cost

Compare flat rate and dose-tier models

The label schedule

Tirzepatide is titrated. The approved schedule runs 2.5 mg for weeks 1 to 4, then 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to 15 mg, escalating roughly every four weeks if tolerated.

The first step is the important one for this article: 2.5 mg is a tolerance-building dose and is not intended to produce weight loss. The first therapeutic dose is 5 mg. In SURMOUNT-1, 5 mg produced about 15.0% mean reduction, 10 mg about 19.5% and 15 mg about 20.9%.

Why this is a pricing article

Because on a dose-tiered programme, the advertised price is usually the 2.5 mg price — the rate for a dose the label describes as preparatory. You will be on it for four weeks and then never again.

Every comparison built on advertised starter prices therefore ranks providers on a figure that applies to the first month of an indefinite treatment. Given SURMOUNT-4's withdrawal findings, that is roughly the least relevant month there is.

Two pricing structures, two different bets

Dose-tiered pricing charges more as you escalate. It looks cheapest at signup and costs most at maintenance. Brand products work this way: Zepbound runs $299 at 2.5 mg, $399 at 5 mg and $449 above that direct from the manufacturer.

Flat-rate pricing charges one price across covered doses. It looks less attractive at signup and does not change when you escalate. Several compounded programmes work this way.

Neither is inherently better. Which wins depends on where you end up, and you will not know that at signup — which is itself the argument for treating the maintenance-dose price as the real one.

The question to ask, in writing

One sentence: what will I pay per month at 10 mg, including every required fee?

Then: does the price change again at 12.5 or 15 mg; is there a supply or dose cap; and if I prepay for twelve months at one dose, what happens when I escalate?

Watch for dose caps as well as escalation. One programme in our dataset offers compounded semaglutide at $199 a month capped at 0.6 mg — below the 2.4 mg used in the STEP trials. A capped programme is not a cheaper version of the same treatment. It is a lower-dose treatment, and the expected effect is correspondingly smaller.

What the label actually directs

Start at 2.5 mg once weekly for four weeks. Increase to 5 mg. Then increase in 2.5 mg increments no sooner than every four weeks, based on tolerability and response, to a maximum of 15 mg.

The recommended maintenance dosages are 5, 10 and 15 mg. The intermediate strengths are titration steps rather than destinations, and the interval is a minimum rather than a schedule. Many patients maintain at 5 or 10 mg.

The sentence that settles the pricing argument

The label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again.

On a dose-tiered programme, that is almost always the dose the advertised price refers to. A comparison built on it ranks providers on a figure nobody pays after month one.

Worked against published rates

Brand Zepbound direct from LillyDirect: $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg upward, with the rate contingent on refilling within 45 days. Following the label, roughly $5,088 across a year.

A flat-rate compounded plan at $186 is $2,232 across the same year. The $2,856 difference comes entirely from dose structure. Neither advertised monthly figure predicts it.

These are different products with different regulatory status, so this is not a like-for-like recommendation. The mechanism is the point.

Dose caps, which are the inverse problem

Some programmes limit the maximum dose rather than charging more for it. One compounded semaglutide programme in our dataset is capped at 0.6 mg against the 2.4 mg used in the STEP trials, at $199 a month; the full-titration version is $279.

A capped programme is a lower-dose treatment with a correspondingly smaller expected effect, not a discounted version of the same one. It should never appear in the same ranking as full-titration programmes, and on this site it does not.

Questions readers actually ask